Safety and Activity of Tarlatamab Combined with PD-L1 Inhibitors as First-Line Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer: Insights from the DeLLphi-303 Phase 1b Study
Posted inOncology

Safety and Activity of Tarlatamab Combined with PD-L1 Inhibitors as First-Line Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer: Insights from the DeLLphi-303 Phase 1b Study

This review synthesizes evidence on tarlatamab plus PD-L1 inhibitors as maintenance therapy post chemo-immunotherapy in extensive-stage SCLC, highlighting safety, clinical activity, and translational implications from the DeLLphi-303 study and contextual literature.
Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study
Posted inClinical Updates Hematology-Oncology Specialties

Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study

Maintenance therapy with romidepsin following autologous hematopoietic stem-cell transplantation (AHCT) in peripheral T-cell lymphoma (PTCL) demonstrated feasibility and an estimated 2-year progression-free survival (PFS) of 62%, though the primary efficacy endpoint was not met in this phase 2 trial.